Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Retained Earnings: 2010-2024

Historic Retained Earnings for Sunshine Biopharma (SBFM) over the last 12 years, with Dec 2024 value amounting to -$69.0 million.

  • Sunshine Biopharma's Retained Earnings fell 8.96% to -$72.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.9 million, marking a year-over-year decrease of 8.96%. This contributed to the annual value of -$69.0 million for FY2024, which is 8.03% down from last year.
  • As of FY2024, Sunshine Biopharma's Retained Earnings stood at -$69.0 million, which was down 8.03% from -$63.9 million recorded in FY2023.
  • In the past 5 years, Sunshine Biopharma's Retained Earnings ranged from a high of -$20.2 million in FY2020 and a low of -$69.0 million during FY2024.
  • For the 3-year period, Sunshine Biopharma's Retained Earnings averaged around -$64.1 million, with its median value being -$63.9 million (2023).
  • Data for Sunshine Biopharma's Retained Earnings shows a maximum YoY crashed of 81.90% (in 2022) over the last 5 years.
  • Sunshine Biopharma's Retained Earnings (Yearly) stood at -$20.2 million in 2020, then slumped by 61.51% to -$32.7 million in 2021, then plummeted by 81.90% to -$59.4 million in 2022, then dropped by 7.59% to -$63.9 million in 2023, then fell by 8.03% to -$69.0 million in 2024.